# Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus

> **NCT07720310** · — · ENROLLING_BY_INVITATION · sponsor: **N.N. Alexandrov National Cancer Centre** · enrollment: 12 (estimated)

## Conditions studied

- System Lupus Erythematosus(SLE)

## Interventions

- **BIOLOGICAL:** CAR T cells chimeric antigen receptor cells

## Key facts

- **NCT ID:** NCT07720310
- **Lead sponsor:** N.N. Alexandrov National Cancer Centre
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-09
- **Primary completion:** 2028-06
- **Final completion:** 2030-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720310, "Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07720310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*